| 0 (0%) | 11-14 12:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.36 |
| Resists | First : | 1 | Second : | 1.16 |
| Pivot price | 0.45  |
|||
| Supports | First : | 0.44 | Second : | 0.1 |
| MAs | MA(5) : | 0.52  |
MA(20) : | 0.42 |
| MA(100) : | 0.6 |
MA(250) : | 1.46 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.1 |
D(3) : | 54.6 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 5.88 | Low : | 0.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ORGS ] has closed below upper band by 23.6%. Bollinger Bands are 2.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.69 - 0.69 | 0.69 - 0.7 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Thu, 13 Nov 2025
Tunisia: Escalating crackdown on human rights organizations reaches critical levels - Amnesty International
Thu, 13 Nov 2025
Enviro group that helped lead Keystone Pipeline opposition suspends US operations - Politico
Thu, 13 Nov 2025
All Things Considered - NPR
Thu, 13 Nov 2025
US designates four groups in Europe as terrorists, calls them 'violent Antifa' - Reuters
Thu, 13 Nov 2025
With government reopened, healthcare orgs press lawmakers to act swiftly on ACA subsidies - Fierce Healthcare
Thu, 13 Nov 2025
Uniting Organizations to Collectively Advocate for Neuromuscular Diseases: Paul Melmeyer, MPP - Neurology Live
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.79e+006 (%) |
| Held by Institutions | 20.1 (%) |
| Shares Short | 41 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.405e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 196.2 % |
| Return on Equity (ttm) | -68.5 % |
| Qtrly Rev. Growth | 899000 % |
| Gross Profit (p.s.) | 81.32 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -331321 |
| Qtrly Earnings Growth | -24.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.43 |
| Dividend | 0 |
| Forward Dividend | 56250 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|